Daily Archives: September 30, 2019
Mon September 30 – 10 Stories of The Day!
30 Sep, 2019 | 01:31h | UTC
Commentaries: Many patients with vaping-related illnesses used THC, CDC reports – STAT (free) AND THC vape products may be the main culprit in the mysterious lung illness outbreak – Vox (free) AND U.S. CDC recommends against using vapes with marijuana ingredient – Reuters (free)
Related: Preliminary Report: Pulmonary Illness Related to E-Cigarette Use (free resources)
2 – Special Issue: Nutrition – ICU Management & Practice (free articles)
– Homepage
– Editorial by Prof. Jean-Louis Vincent, MD, PhD
– New ESPEN Guidelines for Nutrition in the Critically Ill: Help, What Happened!?
– Emerging Concepts in Nutritional Therapy for the Critically Ill Child
– Obesity and Nutrition in Critical Illness
– Objective Malnutrition Diagnosis and Personalised Nutrition Delivery in the ICU
– The Role of Speech and Language Therapy Supporting Nutritional Management in ICU
Infographic: An overview of nutrition management in the ICU
3 – Novelist Cormac McCarthy’s tips on how to write a great science paper – Nature (free)
4 – Understanding acute burn injury as a chronic disease – Burns & Trauma (free)
5 – Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG – TCTMD (free) AND EXCEL: No Significant Outcome Differences in PCI vs CABG for Left Main Coronary Disease at Five Years – American College of Cardiology (free)
Related Meta-Analysis: All-cause mortality and major cardiovascular outcomes comparing percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: a meta-analysis of short-term and long-term randomised trials – OpenHeart (free) AND Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis – JAMA Cardiology (free) AND Percutaneous Coronary Intervention Using Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis: A Meta-Analysis of Randomized Trials – Circulation: Cardiovascular Interventions (free) AND Percutaneous intervention versus coronary artery bypass graft surgery in left main coronary artery stenosis: a systematic review and meta-analysis – BMC Medicine (free) AND Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data – The Lancet (link to abstract – $ for full-text)
Commentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
8 – Men with Prostate Cancer can be Spared Radiotherapy after Surgery [ESMO 2019 Press Release] (free)
See also: ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds – The ASCO Post (free) AND Skipping Radiotherapy After Surgery for Prostate Cancer – Medscape (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
9 – Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
10 – Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC – European Society for Medical Oncology (free) AND Nivolumab/Low-dose Ipilimumab: A Potential Chemotherapy-Sparing Option in Advanced NSCLC – Pharmacy Times (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
CDC Report: 76.9% of Patients with Vaping-related Lung Illnesses Used a THC-Containing Product
30 Sep, 2019 | 00:56h | UTCCommentaries: Many patients with vaping-related illnesses used THC, CDC reports – STAT (free) AND THC vape products may be the main culprit in the mysterious lung illness outbreak – Vox (free) AND U.S. CDC recommends against using vapes with marijuana ingredient – Reuters (free)
Related: Preliminary Report: Pulmonary Illness Related to E-Cigarette Use (free resources)
Special Issue: Nutrition in Critical Illness
30 Sep, 2019 | 00:50h | UTCHomepage: Nutrition – ICU Management & Practice (free articles)
– Editorial by Prof. Jean-Louis Vincent, MD, PhD
– New ESPEN Guidelines for Nutrition in the Critically Ill: Help, What Happened!?
– Emerging Concepts in Nutritional Therapy for the Critically Ill Child
– Obesity and Nutrition in Critical Illness
– Objective Malnutrition Diagnosis and Personalised Nutrition Delivery in the ICU
– The Role of Speech and Language Therapy Supporting Nutritional Management in ICU
Infographic: An overview of nutrition management in the ICU
Tips on How to Write a Great Science Paper
30 Sep, 2019 | 00:48h | UTCNovelist Cormac McCarthy’s tips on how to write a great science paper – Nature (free)
[Abstract Only] Randomized Trial: Similar Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
30 Sep, 2019 | 00:44h | UTCFive-Year Outcomes after PCI or CABG for Left Main Coronary Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG – TCTMD (free) AND EXCEL: No Significant Outcome Differences in PCI vs CABG for Left Main Coronary Disease at Five Years – American College of Cardiology (free)
Related Meta-Analysis: All-cause mortality and major cardiovascular outcomes comparing percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: a meta-analysis of short-term and long-term randomised trials – OpenHeart (free) AND Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis – JAMA Cardiology (free) AND Percutaneous Coronary Intervention Using Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis: A Meta-Analysis of Randomized Trials – Circulation: Cardiovascular Interventions (free) AND Percutaneous intervention versus coronary artery bypass graft surgery in left main coronary artery stenosis: a systematic review and meta-analysis – BMC Medicine (free) AND Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data – The Lancet (link to abstract – $ for full-text)
Related Commentary on Twitter
In an RCT, 1905 patients with left main coronary artery disease were assigned to either PCI or CABG. At five years, rates of the composite of death, stroke, or MI were not significantly different between the two groups. See the EXCEL trial. #TCT2019 https://t.co/wlpE5FPTwT
— NEJM (@NEJM) September 28, 2019
Review: Understanding Acute Burn Injury as a Chronic Disease
30 Sep, 2019 | 00:47h | UTCUnderstanding acute burn injury as a chronic disease – Burns & Trauma (free)
Global Burden of Cancer, 1990 to 2017
30 Sep, 2019 | 00:42h | UTC
Related Commentary on Twitter
To ensure sustainable global development, increased efforts are needed in cancer prevention and in ensuring universal access to cancer care. https://t.co/6HDaU8Ped9
— JAMA Oncology (@JAMAOnc) September 27, 2019
#ESMO19 – Randomized Trial: Improved Overall Survival with a CDK4/6 Inhibitor for Hormone Receptor-positive, ERBB2-negative Advanced Breast Cancer
30 Sep, 2019 | 00:40h | UTCCommentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
[Abstract Only] Randomized Trial: Standard Valsalva vs. Modified Valsalva for Cardioversion of SVT
30 Sep, 2019 | 00:14h | UTCStandard Valsalva vs Modified Valsalva for Cardioversion of SVT? – REBELEM (free)
Original Study: A multicenter randomized controlled trial of a modified Valsalva maneuver for cardioversion of supraventricular tachycardias – The American Journal of Emergency Medicine (link to abstract – $ for full-text)
Related Study: Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial – The Lancet (free), Commentaries: Supraventricular tachycardia: back to basics – The Lancet (free) AND The REVERT Trial: A Modified Valsalva Maneuver to Convert SVT – REBELEM (free)
#ESMO19 – [Not Published Yet] Randomized Trial: Many Men with Prostate Cancer May Avoid Postoperative Radiotherapy, Study Suggests
30 Sep, 2019 | 00:39h | UTCMen with Prostate Cancer can be Spared Radiotherapy after Surgery [ESMO 2019 Press Release] (free)
See also: ESMO 2019: Men With Prostate Cancer May Avoid Postoperative Radiotherapy, Study Finds – The ASCO Post (free) AND Skipping Radiotherapy After Surgery for Prostate Cancer – Medscape (free registration required)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
30 Sep, 2019 | 00:37h | UTCFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
Related Commentary on Twitter
With a 5-year min follow-up, the combination of nivolumab plus ipilimumab associated with 5-year survival of 52% in patients with metastatic #melanoma, compared with 44% for nivolumab alone and 26% for ipilimumab alone. See the CheckMate 067 trial. #ESMO19 https://t.co/f50KNzH5tp
— NEJM (@NEJM) September 28, 2019
#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer
30 Sep, 2019 | 00:35h | UTCNivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC – European Society for Medical Oncology (free) AND Nivolumab/Low-dose Ipilimumab: A Potential Chemotherapy-Sparing Option in Advanced NSCLC – Pharmacy Times (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
Related Commentary on Twitter
Chemo-naïve patients with adv #NSCLC with PD-L1 expression assigned to nivolumab + ipilimumab, nivolumab alone, or chemo. Patients receiving nivolumab + ipilimumab had better clin outcomes. See the CheckMate 227 trial. #ESMO19 https://t.co/jU9S62qZLa
— NEJM (@NEJM) September 28, 2019
Cohort Study: Improved Survival After Mohs Micrographic Surgery for Early-Stage Invasive Melanoma
30 Sep, 2019 | 00:12h | UTCComparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma – JAMA Dermatology (free for a limited period)
Editorial: Improving Survival for Patients With Early-Stage Melanoma (free for a limited period)
Commentaries: Mohs micrographic surgery may up survival in stage I melanoma – MedicalXpress (free) AND Mohs Tied to Better OS in Early Invasive Melanoma – MedPage Today (free registration required)
Related: Mohs Surgery for the Treatment of Skin Cancer: A Review of Guidelines – Canadian Agency for Drugs and Technologies in Health (free)
Review: Treatment of Vulvovaginal Atrophy
30 Sep, 2019 | 00:12h | UTCTreatment of Vulvovaginal Atrophy – JAMA (free for a limited period)
Randomized Trial: Protocolized Non-invasive vs. Invasive Weaning from Mechanical Ventilation for Adults in Intensive Care
30 Sep, 2019 | 00:16h | UTCSource: Critical Care Reviews Newsletter
“A protocolized non-invasive weaning strategy did not reduce time to liberation from ventilation. However, patients who underwent non-invasive weaning had fewer days requiring IMV and required fewer antibiotics for respiratory infections.”
[Abstracts Only] Biologics Found to be Effective for Ulcerative Colitis in Industry-funded Trials
30 Sep, 2019 | 00:11h | UTCSee also: Ulcerative Colitis: One Biologic Investigated, Two Others Compared – NEJM Journal Watch (free)
Original Studies: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text) AND Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)
Randomized Trial: Length of Steroid Course for Childhood Nephrotic Syndrome Makes Little Difference to Later Recurrences
30 Sep, 2019 | 00:10h | UTCOriginal Study: Randomized Trial: Long Term Tapering vs. Standard Prednisolone Treatment for First Episode of Childhood Nephrotic Syndrome – The BMJ (free)
WHO 2019 Monitoring Report: Primary Health Care on the Road to Universal Health Coverage
30 Sep, 2019 | 00:09h | UTCNews Release: Countries must invest at least 1% more of GDP on primary health care to eliminate glaring coverage gaps – World Health Organization (free)
See also: WHO welcomes landmark UN declaration on universal health coverage – World Health Organization (free)
Massive Open Online Courses (MOOCs) for Continuing Medical Education – Why and How?
30 Sep, 2019 | 00:08h | UTC
Randomized Trial: New Antibiotic Seems Effective for Community-Acquired Bacterial Pneumonia
30 Sep, 2019 | 00:07h | UTCOral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Lefamulin—A New Antibiotic for Community-Acquired Pneumonia (free for a limited period)
Related Commentary on Twitter
Among patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose https://t.co/wwQrx79kFq
— JAMA (@JAMA_current) September 28, 2019
[Abstract Only] Systematic Review: A Majority of Anterior Cruciate Ligament Injuries Can Be Prevented by Injury Prevention Programs
30 Sep, 2019 | 00:06h | UTCA Majority of Anterior Cruciate Ligament Injuries Can Be Prevented by Injury Prevention Programs: A Systematic Review of Randomized Controlled Trials and Cluster–Randomized Controlled Trials With Meta-analysis – American Journal of Sports Medicine (link to abstract – $ for full-text)
Source: EvidenceAlerts